Clinical and experimental use of probiotic formulations for management of end-stage renal disease: an update (Q38098897)

28 August 2017

Clinical and experimental use of probiotic formulations for management of end-stage renal disease: an update (English)

1 reference

28 August 2017

0 references

1 reference

Alessandro Di Cerbo

1

0 references

Beniamino Palmieri

object named as

Beniamino Palmieri

series ordinal

6

0 references

Tommaso Iannitti

series ordinal

5

object named as

Tommaso Iannitti

1 reference

28 August 2017

2

Federica Pezzuto

1 reference

28 August 2017

4

Valentina Rottigni

1 reference

28 August 2017

Lucia Palmieri

3

1 reference

PubMed ID

23584675

28 August 2017

language of work or name

1 reference

13 April 2013

1 reference

International Urology and Nephrology

28 August 2017

1 reference

28 August 2017

45

1 reference

28 August 2017

1569-1576

1 reference

28 August 2017

6

1 reference

Therapeutical use of probiotic formulations in clinical practice.

28 August 2017

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0335-5

Immunomodulatory function of lactic acid bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0335-5

Gut changes attributed to ageing: effects on intestinal microflora

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0335-5

Patterns of cytokine induction by gram-positive and gram-negative probiotic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0335-5

Bacterial probiotic modulation of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0335-5

Modulation of human dendritic cell phenotype and function by probiotic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0335-5

Effect of probiotics on pro-inflammatory cytokines and NF-kappaB activation in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0335-5

Cholesterol-lowering effects of probiotics and prebiotics: a review of in vivo and in vitro findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0335-5

Review on uremic toxins: classification, concentration, and interindividual variability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0335-5

What is new in uremic toxicity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0335-5

Mineral metabolism disturbances in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0335-5

New discoveries in the pathogenesis of renal osteodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0335-5

Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0335-5

Bone and the kidney: a systems biology approach to the molecular mechanisms of renal osteodystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0335-5

Patients with chronic renal failure have abnormal small intestinal motility and a high prevalence of small intestinal bacterial overgrowth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0335-5

Small intestinal bacterial overgrowth syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0335-5

Chronic kidney disease alters intestinal microbial flora

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0335-5

Kidney stones and kidney function loss: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0335-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0335-5

Oxalate-degrading bacteria of the human gut as probiotics in the management of kidney stone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0335-5

Oxalobacter formigenes and its role in oxalate metabolism in the human gut.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0335-5

Prevention of nephrolithiasis by Lactobacillus in stone-forming rats: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0335-5

Metabolic activity of probiotics-oxalate degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0335-5

Oxalobacter formigenes may reduce the risk of calcium oxalate kidney stones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0335-5

Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0335-5

Intestinal Oxalobacter formigenes colonization in calcium oxalate stone formers and its relation to urinary oxalate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0335-5

Use of a probiotic to decrease enteric hyperoxaluria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0335-5

Effects of Lactobacillus casei and Bifidobacterium breve on urinary oxalate excretion in nephrolithiasis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0335-5

Oxalate degrading bacteria: new treatment option for patients with primary and secondary hyperoxaluria?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0335-5

Probiotic amelioration of azotemia in 5/6th nephrectomized Sprague-Dawley rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0335-5

In vitro and in vivo assessment of intraintestinal bacteriotherapy in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0335-5

Bifidobacterium in gastro-resistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0335-5

p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0335-5

Effects of synbiotic treatment on serum level of p-cresol in haemodialysis patients: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0335-5

Probiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease: a 6-month pilot scale trial in Canada.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0335-5

Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0335-5

A Randomized, Controlled Trial of Lactic Acid Bacteria for Idiopathic Hyperoxaluria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0335-5

Dietary probiotic supplementation enhances natural killer cell activity in the elderly: an investigation of age-related immunological changes

21 January 2018

1 reference

12 December 2020

Disordered intestinal mechanisms in patients with chronic kidney failure

1 reference

12 December 2020

Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis

1 reference

12 December 2020

Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019

1 reference

12 December 2020

K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification

1 reference

12 December 2020

Bacterial populations of the small intestine in uremia

1 reference

12 December 2020

Epidemiology of chronic kidney disease

1 reference

12 December 2020

Small intestinal bacterial overgrowth

1 reference

12 December 2020

Biomodulation of the toxic and nutritional effects of small bowel bacterial overgrowth in end-stage kidney disease using freeze-dried Lactobacillus acidophilus.

1 reference

12 December 2020

Chronic kidney disease epidemic: myth and reality

1 reference

12 December 2020

Effect of Bifidobacterium bifidum and Lactobacillus acidophilus on gut mucosa and peripheral blood B lymphocytes

1 reference

12 December 2020

Modulation of a specific humoral immune response and changes in intestinal flora mediated through fermented milk intake

1 reference

12 December 2020

Effect of oral intake of an enteric capsule preparation containing Bifidobacterium longum on the progression of chronic renal failure

1 reference

12 December 2020

Effect of bifidobacteria on nitrites and nitrosamines

1 reference

12 December 2020

Ureteric pain in patients with chronic renal failure on hemodialysis. Diagnostic approach with ultrasonography and computer tomography

1 reference

12 December 2020

Uremic toxicity: present state of the art.

1 reference

12 December 2020

Rapid reversal of hyperoxaluria in a rat model after probiotic administration of Oxalobacter formigenes

1 reference

12 December 2020

Twenty-four-hour urine chemistries and the risk of kidney stones among women and men.

1 reference

12 December 2020

10.1007/S11255-012-0335-5

Identifiers

DOI

1 reference

release_plz4z4xs4nbr5b6lyfqd5drclm

28 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/plz4z4xs4nbr5b6lyfqd5drclm

24 November 2022

mapped directly with Wikidata item

PubMed ID

23584675

1 reference

PubMed ID

23584675